Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Leukemia & Lymphoma

Font Size

New Non-Hodgkin's Lymphoma Drug Passes Hurdle

Bexxar May Have Potential as Initial Treatment for Follicular Lymphoma

WebMD Health News

Feb. 2, 2005 - A new type of lymphoma treatment that combines cancer-killing antibodies and radiation may have potential as a powerful initial attack against an advanced form of non-Hodgkin's lymphoma, according to a new study.

Researchers found a one-week treatment with Bexxar induced a complete remission of the disease that lasted more than five years in most patients with previously untreated follicular lymphoma.

Although these results are exciting, experts say the treatment does not constitute a "cure" for this type of non-Hodgkin's lymphoma. This was a small study on the effectiveness of Bexxar as a first line of treatment in patients with advanced disease, and more research on this approach is required before it can be approved by the FDA for widespread use.

Follicular lymphoma is the second most common form of non-Hodgkin's lymphoma and accounts for more than 20% of all cases. Follicular lymphoma is cancer of the lymph nodes, which are an important part of the immune system, the body's natural defense system against infection.

Bexxar combines the antibody (tositumomab) with radioactive iodine and is administered through an infusion. The antibody stimulates the body's immune system to fight the cancer.

The drug was approved by the FDA in 2003 for the treatment of follicular, non-Hodgkin's lymphoma in patients who have not responded to initial therapy with the drug Rituxan and who have relapsed following chemotherapy. But this is the first study to use the drug in previously untreated patients.

New First-Line Treatment for Lymphoma?

In the study, researchers tested the drug in 76 patients with advanced follicular lymphoma (stage III and IV) who had not yet been treated for their disease. The patients were given a one-week treatment with Bexxar and were followed for about five years.

The results appear in the Feb. 3 issue of The New England Journal of Medicine.

Researchers found that 95% of the patients responded to the treatment; 75% had a complete disappearance of the signs of their cancer.

After follow-up, the estimated five-year overall survival rate was 89%. Fifty-one percent of patients survived during this period with no evidence that their cancer continued to progress.

Today on WebMD

stem cells
What are they and why do we need them?
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Do you know the symptoms?
Vitamin D
New Treatments For Non-Hodgkins Lymphoma
Lifestyle Tips for Depression Slideshow
Pets Improve Your Health